Physician profile
Norman Burns
NPI 1891793402
$32,679.71
in general payments reported to CMS, 2019-2025
81 companies · $4,954 in 2025
The $4,954 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,469 · 2020: $4,199 · 2021: $3,459 · 2022: $5,178 · 2023: $5,843 · 2024: $5,579 · 2025: $4,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,136.76 |
| Education | $238.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,730.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $2,484.46 | 2019-2025 | |
| Abbvie INC. | $1,992.01 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Biogen, INC. | $1,915.00 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $1,768.13 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Celgene Corporation | $1,553.07 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $1,362.04 | 2019-2025 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $1,187.44 | 2019-2023 | Qelbree |
| Genzyme Corporation | $966.04 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $899.42 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $887.03 | 2019-2025 | |
| Amgen INC. | $820.69 | 2019-2025 | Uplizna, Aimovig |
| Eisai INC. | $820.19 | 2019-2025 | |
| Lundbeck LLC | $812.88 | 2019-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $733.17 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.